Amgen, Cytokinetics, Servier Unveil New Results from Omecamtiv Mecarbil Study

Date : 11/18/2019 @ 2:46PM
Source : Dow Jones News
Stock : Amgen Inc (AMGN)
Quote : 237.64  -3.85 (-1.59%) @ 8:52PM

Amgen, Cytokinetics, Servier Unveil New Results from Omecamtiv Mecarbil Study

Historical Stock Chart

3 Months : From Oct 2019 to Jan 2020

Click Here for more Amgen Charts.

By Michael Dabaie


Amgen Inc. (AMGN), Cytokinetics Inc. (CYTK) and Servier announced that new results from a Phase 2 trial showed omecamtiv mecarbil in patients with heart failure with reduced ejection fraction was associated with neutral or improved measures of diastolic function.

In addition to previously reported improvements in cardiac contractility measures, measures of diastolic function weren't different from placebo and, for some measures, trended towards improvement, the companies said.

In the COSMIC-HF trial, 448 patients were randomly assigned to omecamtiv mecarbil or placebo in a double-blind fashion for 20 weeks.


Write to Michael Dabaie at


(END) Dow Jones Newswires

November 18, 2019 09:31 ET (14:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.